Progenics Pharmaceuticals (PGNX +2.2%) reports positive clinical data from a completed Phase 1...


Progenics Pharmaceuticals (PGNX +2.2%) reports positive clinical data from a completed Phase 1 study of PSMA ADC, an antibody-drug conjugate designed to selectively deliver chemotherapy to cells that express prostate-specific membrane antigen. The tests showed the drug was generally well tolerated in patients at doses up to and including the maximum tolerated dose.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs